Articles tagged with Antigens
A new therapy developed at Cedars-Sinai Medical Center improves transplant rates and outcomes for patients awaiting living- and deceased-donor kidney transplantation. The combination of IVIG and rituximab offers superior benefits to IVIG alone, improving transplant rates to 80 percent of treated patients.
The researchers have developed a biologically engineered organism that can effectively deliver an antigen in the body using live salmonella bacterium. The new method is a major step forward in developing a means of biological containment for vaccine delivery, making vaccines more affordable for developing countries.
A retrospective cohort study found complex gender interactions in kidney transplantation outcomes, with female donors having a higher rate of graft loss and female recipients experiencing a lower rate of graft failure. The study suggests considering sex in future studies and decisions on organ allocation to optimize transplant success.
Researchers successfully treated a patient with Stage 4 melanoma using cloned infection-fighting T cells, achieving long-term remission. The treatment showed promising results, with the entire tumor regressing despite only 50% of tumor cells expressing the targeted antigen.
A new study presents radioimmunotherapy targeting viral antigens as a novel option to treat or prevent many viral cancers. The therapy offers 'exquisite specificity' in targeting cancer cells expressing viral antigens, allowing for more precise diagnosis and treatment.
Researchers at Tufts University have discovered how cell surface receptors cooperate to generate immune responses, revealing the importance of integrin VLA-4 in facilitating signal transmission. This understanding is crucial for developing interventions to enhance or inhibit immune responses, particularly in autoimmune diseases.
A protein sequence associated with Huntington's disease has been identified as a potential life-saving vaccine component. The polyQ-based adjuvant efficiently enhances both branches of the immune response to a poor model antigen, with no apparent toxicity in mice.
Cure Lab, Inc. has developed a new technology that combines two forms of vaccine antigens: one easily processed by the proteosome and another resistant to it. This combination elicits a stronger immune response than using either form alone, promising improved vaccine efficiency.
Scientists at The Wistar Institute have developed a novel vaccine design strategy that uses a herpes simplex protein to block a specific receptor molecule on antigen-presenting cells. This allows for a stronger immune response and potential protection against viral diseases like AIDS and cervical cancer.
Researchers report that Tregs respond stronger to foreign substances than their own body proteins, contrary to the long-held scientific belief. This finding has implications for emerging therapies targeting autoimmune diseases.
Researchers developed a novel antigen-sparing adjuvant strategy to improve immunogenicity of the bird flu vaccine. The new formulation showed significant cross-clade immunity against H5N1 viruses and induced high levels of neutralizing antibodies, increasing protection against pandemic.
A recent review examines the evidence supporting PSA testing for prostate cancer screening. Despite controversy over its effectiveness, many Canadian men are being tested due to widespread practice. The article also discusses finasteride's potential in reducing enlarged prostate risks and cancer risk.
Researchers found that unrelated umbilical cord blood transplants can provide similar five-year survival rates to allele-matched bone marrow transplants for children with acute leukemia. However, matched cord blood transplants showed greater survival rates but required further study to confirm.
Researchers will investigate the mechanisms of chronic rhinosinusitis (CRS), a debilitating airway disease affecting millions worldwide. They aim to identify specific fungal antigens contributing to the pathology and develop novel treatments.
A new study found that rotavirus, a common cause of diarrhea in children, can also be present systemically, with infectious virus detected in the blood of infected children. The presence of virus in the blood is directly related to the presence of antigen but independent of diarrhea.
Researchers at The Wistar Institute have developed a novel antigen-cloning technique that may boost efforts to develop a melanoma vaccine. The new approach has been used to identify a tumor antigen called ribosomal protein L8 (RPL8), which has the potential to elicit both helper T cell and cytotoxic T-lymphocyte responses.
New study finds that PSA measurement is associated with prostate cancer prognosis but poorly predicts lethal cancer. Researchers emphasize the need for improved surveillance strategies to identify life-threatening tumors.
Dr. Russell is recognized for his contributions to understanding the protein antigens on Streptococcus mutans, a bacterium associated with dental caries. His work has led to the development of immunological interventions targeting this adhesin and improved mucosal immune response strategies.
A new study found that the most commonly used malaria vaccine may not be effective against the prevalent strain in Mali. The researchers discovered that only 16% of infections were caused by the strain included in the vaccine, highlighting the importance of testing vaccines in diverse populations.
Researchers used two-photon microscopy to visualize T lymphocyte infiltration into solid tumours in real-time. T lymphocytes target tumour cells by recognizing the antigen and binding with enzymes, ultimately leading to cell death.
A study found that men with high PSA velocity had a lower survival rate (54%) compared to those with low velocity (92%). The study suggests that PSA velocity may be used to predict outcomes for prostate cancer patients.
Researchers have developed a novel strategy for cancer vaccine development using Salmonella typhimurium as a delivery vehicle. The study successfully elicited immune responses against NY-ESO-1, a known tumor cell antigen, and showed regression of established tumors in mice.
A new mouse model has been developed to induce melanoma with a defined cancer antigen, closely mimicking human tumors. This model allows for detailed immunological analyses before and after vaccination, which may lead to a better understanding of spontaneous melanoma regressions and the optimization of cancer vaccine timing.
Researchers have developed a strategy to overcome biological obstacles in cell therapy for cancer by stimulating tumor-reactive T cells with interleukin-15. This approach has shown promise in treating disseminated forms of leukemia in mice without damaging other tissues.
A new plant-based system rapidly produces high levels of antigens that confer immunity against the plague. Guinea pigs vaccinated with the new antigen exhibited higher survival rates compared to traditional vaccines.
Researchers at NYU Langone Health and University of California, Berkeley, have observed the exchange of information between immune cells that sparks a body-wide response to infection. The study reveals how T cells analyze and react to signals of infection at the immunological synapse.
A study of 1,492 men found that annual PSA testing reduced the risk of dying from prostate cancer by 3.6%, while increasing the chances of diagnosis with curable cancers. The test measures levels of prostate-specific antigen, a protein produced by the prostate.
Researchers found that kidney paired donation (KPD) transplants can be performed with outcomes similar to compatible living donor kidney transplants, offering a cost savings and decrease in waiting time. A national KPD transplant scheme could enable many more transplants for patients with incompatible donors.
Scientists discover that constant stimulation of antigens is necessary to maintain anergy in self-reactive B cells, which can lead to autoimmune diseases. The study suggests that pro-inflammatory products or bacterial infections may trigger the loss of anergy and activate these cells.
Researchers at the University of Pennsylvania School of Medicine have developed a cancer vaccine that uses the bacterium Listeria monocytogenes to boost an immune response against breast tumor-associated antigens. The vaccine was tested in mice with established breast tumors, resulting in complete tumor eradication after 100 days.
A virus can adapt the host's gene silencing machinery to evade the immune response by using microRNAs to silence a key protein target. This finding bolsters evidence that microRNAs play important roles in infected cells, challenging the long-held notion of their sole role as an antiviral defense mechanism.
Researchers found that injecting a wart with a skin test antigen from mumps, Candida, or Trichophyton can clear the wart and other distant warts. Patients who responded to treatment were more likely to have an immune response to HPV, suggesting intralesional immunotherapy induces HPV-directed immunity.
A new blood test, EPCA, has been shown to be highly sensitive and specific in detecting prostate cancer. The test was found to have an accuracy rate of 94% and has the potential to reduce unnecessary biopsies and undetected tumors.
Researchers observed B cells' random and directed migration to helper T cells, guided by chemokine receptor CCR7 and cognate antigen. The interaction enables stable formation of motile conjugates with activated T cells.
A Medical College of Georgia researcher has developed a mouse model to study the immune system's initial response to cancer. The goal is to understand how the body decides which cancer cells to attack and which to ignore, in hopes of developing new treatments that utilize the body's natural defenses.
Researchers have made significant progress in developing a breast cancer vaccine, using a protein called mammaglobin-A found in 80% of breast tumors. The DNA vaccine has been shown to stimulate an immune response that can recognize and attack tumor cells expressing the protein.
QS-21A has been shown to significantly improve the body's immune response in vaccine therapies against aggressive diseases such as melanoma and HIV-1. By improving its potency, QS-21A could save patients money on expensive vaccines and stretch limited supplies.
A Yale research group found that CTCL cells require antigenic stimuli delivered by Langerhans cells to replicate. The study identified cryptic self-antigens presented by LC to CTCL receptors, stimulating rapid division and regulatory T cell formation.
Research reveals that SV40 large T antigen binds to tumor suppressor Fbw7, hijacking its function to promote tumorigenesis. This interaction highlights the importance of Fbw7 as a potential therapeutic target for cancer treatment strategies.
Researchers developed T cells targeting Epstein Barr virus antigens to treat advanced nasopharyngeal carcinoma. Six out of ten patients remained disease-free after treatment, with some experiencing partial remission.
A new vaccine has been developed using a pathogen-mimicking approach, combining CpG 7909 adjuvant and synthetic peptide from melanoma antigen Melan-A/MART-1. The vaccine induced strong T cell responses in all eight patients, with one order of magnitude higher than previous studies.
Researchers discovered a jumping gene called Hermes, which creates changes in DNA similar to those created by the process behind antigen recognition. This discovery provides evidence that genetic processes behind antigen diversity may have evolved from the activity of a jumping gene.
Research by Emory University scientists found that chronic viral infections fail to develop long-term immune memory cells due to poor cytokine response. The study suggests that rest from antigen exposure is crucial for developing these memory cells.
The Oregon Health & Science University will focus on tuberculosis research, using cells from TB patients with successful immune responses to create vaccines. The goal is to provide protection to others while over 2 million people die worldwide each year of TB.
A genetically engineered listeria bacteria-based vaccine has shown promising results in targeting metastatic cancer cells, inducing a strong innate and acquired immune response. The vaccine, aiming to target pancreatic and ovarian cancers, could potentially be used to prevent recurrence after surgery and chemotherapy.
A research team has identified a new pathway for the display of foreign proteins to the immune system, distinct from the conventional TAP-dependent pathway. This alternative pathway requires cysteine proteases and contributes to immunity against viruses and transplanted tissues.
A vaccine targeting cancer-related antigens in glioblastoma cells appears to prolong patient survival by a median of 103 weeks. The dendritic cell vaccine generated an immune response against these antigens, significantly improving survival rates compared to patients without the treatment.
Researchers solved the puzzle of the molecular structure of the protective antigen protein and CMG2 bound together, providing clearer targets for shutting down the anthrax toxin's entry into cells. This detailed image also points to a potential new tumor treatment using a genetically modified anthrax toxin.
Researchers at Brigham and Women's Hospital have developed a strategy using small interfering RNA to enhance cancer treatment in cases of drug resistance. They tested their theory in a form of leukemia that is resistant to commonly used anti-cancer drugs.
A study by Dana-Farber Cancer Institute researchers found that 36 out of 181 patients with Waldenstrom's macroglobulinemia had at least one first-degree relative with the disease. The study also found no discernible differences in age of onset, blood counts, or genetic analysis between family and non-family forms of the disease.
Researchers have identified a new biomarker, EPCA, which may enable early detection and treatment of prostate cancer. The study found that EPCA was expressed in tissue samples from patients with prostate cancer who initially had negative biopsies.
Researchers have identified a key antigen underlying Crohn disease, bacterial flagellin, which triggers an immune response. Studies found high reactivity against specific flagellins in CD patients, but not in controls or ulcerative colitis patients, providing new leads for causal antigens.
Researchers found that cancer tumors reduce the release of interferon gamma and expression of perforin in CD8 T cells, disabling their ability to destroy cancer cells. However, these defects can be reversed with laboratory growth using immunological factors.
Researchers equipped dendritic cells with genetic material from patient's tumor and PAMPs to break T-cell tolerance, enabling activation of immune system. This approach merges strengths of viral vaccines with ease of using patient's own immune system.
Research at Ohio State University found that acute stress can significantly boost the immune system's response, with stressed animals showing a two-to-four times higher reaction to chemical or protein antigens. This effect was observed even after several weeks to months of re-exposure without further restraint.
A new vaccine targets both the anthrax bacterium and its toxins, demonstrating improved effectiveness in mice tests. The dual-action approach also holds promise as a therapeutic vaccine to help those already infected control the bacteria over time.
A recent study by Christian Larsen and colleagues reveals that a specific threshold of memory cells is necessary to promote rejection, while CD8+ central memory cells mediate rejection. The authors suggest testing for potential cellular sensitization against donors prior to tolerance protocols to increase human transplantation success.
Researchers have developed microgel polymer beads that can be engineered to break apart in acidic conditions, releasing vaccine antigens on the surface of immune cells. This technique avoids destroying protein antigens with stomach acids, making it a promising approach for future vaccines and gene therapy.
Researchers designed a DNA vaccine that stimulates the immune system to recognize and attack proliferating blood vessels in tumors, depriving them of oxygen and nutrients. The vaccine has shown promise in preventing effective angiogenesis and inhibiting tumor growth, offering potential for novel cancer therapies.
A new heat-denatured p24 antigen test has been found to be comparable in effectiveness to existing CD4 lymphocyte count and HIV-1 RNA viral load tests. The test, which costs significantly less, could be a game-changer for developing countries struggling with high HIV infection rates.